0000000001225055

AUTHOR

A Vitale

showing 12 related works from this author

Development and implementation of the AIDA International Registry for patients with Behçet's disease

2022

AbstractPurpose of the present paper is to point out the design, development and deployment of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to pediatric and adult patients with Behçet’s disease (BD). The Registry is a clinical physician-driven non-population- and electronic-based instrument implemented for the retrospective and prospective collection of real-life data about demographics, clinical, therapeutic, laboratory, instrumental and socioeconomic information from BD patients; the Registry is based on the Research Electronic Data Capture (REDCap) tool, which is thought to collect standardised information for clinical real-life research, and has been rea…

AdultRegistrieAutoinflammatory diseaseRegistrySettore MED/16 - REUMATOLOGIAprecision medicinebehçet’s diseaseSettore MED/38 - Pediatria Generale E SpecialisticaRetrospective StudieInternal MedicineHumansProspective StudiesRegistriesChildinternational registryRetrospective StudiesBehçet's diseaseautoinflammatory diseases; behçet’s disease; international registry; precision medicine; rare diseases; uveitisBehcet Syndromerare diseasesautoinflammatory diseasesProspective StudieUveitiEmergency MedicineuveitisRare diseaseHuman
researchProduct

Preliminary data revealing efficacy of Streptococcus salivarius K12 (SSK12) in Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adeniti…

2023

ObjectiveTo evaluate the potential role of Streptococcus salivarius K12 (SSK12) in controlling febrile flares in patients with Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome. Further aims were to assess the impact of SSK12 on (i) flare duration, (ii) variation in the degree of the highest body temperature during flares, (iii) steroid-sparing effect, and (iv) change of PFAPA accompanying symptoms before and after SSK12 introduction.Patients and methodsThe medical charts from 85 pediatric patients with PFAPA syndrome (49 males and 36 females) enrolled in the AIDA registry and treated with SSK12 for a median period of 6.00 ± 7.00 months in the period b…

International Registry PFAPA syndrome Streptococcus salivarius K12 autoinflammatory disease probiotic prophylaxis tonsillitisSettore MED/38 - Pediatria Generale E SpecialisticaAutoinflammationGeneral MedicineHuman medicinePFAPA syndromeFrontiers in Medicine
researchProduct

Searches for rare or forbidden semileptonic charm decays

2011

We present searches for rare or forbidden charm decays of the form $X_c^+\to h^\pm\ell^\mp\ell^{(\prime)+}$, where $X_c^+$ is a charm hadron ($D^+$, $D^+_s$, or $\Lambda_c^+$), $h^\pm$ is a pion, kaon, or proton, and $\ell^{(\prime)\pm}$ is an electron or muon. The analysis is based on $384 fb^{-1}$ of $e^+e^-$ annihilation data collected at or close to the $\Upsilon(4S)$ resonance with the BaBar detector at the SLAC National Accelerator Laboratory. No significant signal is observed for any of the 35 decay modes that are investigated. We establish 90% confidence-level upper limits on the branching fractions between $1 \times 10^{-6}$ and $44 \times 10^{-6}$ depending on the channel. In most…

Semileptonic decayNuclear and High Energy PhysicsParticle physicsforbiddenMesonElectron–positron annihilationFOS: Physical sciencessemileptonic charm decays01 natural sciencesHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)Particle decayPion0103 physical sciencessemileptonic[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Nuclear Experiment010306 general physicsPhysicsMuon010308 nuclear & particles physicsBranching fractionParticle physicsBABAR detectorrareHEPcharm decays3. Good healthCharmed baryonsBaBarPACS: 11.30.Fs 11.30.Hv 13.20.Fc 13.30.CeHigh Energy Physics::Experimentrare; forbidden; semileptonic; charm decaysFísica de partículesExperiments
researchProduct

Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer

2017

The debate about the best approach to select patients with hepatocellular cancer (HCC) waiting for liver transplantation (LT) is still ongoing. This study aims to identify the best variables allowing to discriminate between "high-" and "low-benefit" patients. To do so, the concept of intention-to-treat (ITT) survival benefit of LT has been created. Data of 2,103 adult HCC patients consecutively enlisted during the period 1987-2015 were analyzed. Three rigorous statistical steps were used in order to create the ITT survival benefit of LT: the development of an ITT LT and a non-LT survival model, and the individual prediction of the ITT survival benefit of LT defined as the difference between…

Malemedicine.medical_specialtySettore MED/18 - CHIRURGIA GENERALEmedicine.medical_treatment030230 surgeryMilan criteriaLiver transplantation03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicineCarcinoma Hepatocellular; Europe; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Liver Transplantation; HepatologyHumansRisk factorHepatology; hepatocellular cancer; liver transplantationCarcinoma Hepatocellular; Europe; Female; Humans; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Liver TransplantationSurvival analysisRetrospective StudiesIntention-to-treat analysisHepatologybusiness.industryCarcinomaLiver NeoplasmsRetrospective cohort studyHepatocellularHepatologyMiddle Agedmedicine.diseaseSurgeryLiver TransplantationSettore MED/18Europehepatocellular cancer030211 gastroenterology & hepatologyFemalebusiness
researchProduct

Study of radiative bottomonium transitions using converted photons

2011

We use 111+/-1 million Upsilon(3S) and 89+/-1 million Upsilon(2S) events recorded by the BaBar detector at the PEP-II B-factory at SLAC to perform a study of radiative transitions between bottomonium states using photons that have been converted to e+e- pairs by the detector material. We observe Upsilon(3S) -> gamma chi_b0,2(1P) decay, make precise measurements of the branching fractions for chi_b1,2(1P,2P) -> gamma Upsilon(1S) and chi_b1,2(2P) -> gamma Upsilon(2S) decays, and search for radiative decay to the eta_b(1S) and eta_b(2S) states.

Nuclear and High Energy PhysicsParticle physicsMesonElectron–positron annihilationHadronbottomoniumFOS: Physical sciences01 natural sciencesHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)Particle decayBaBar detector at SLAC; radiative bottomonium transitions0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Radiative transfer010306 general physicsPACS: 13.20.Gd 14.40.PqPhysics010308 nuclear & particles physicsBranching fractionParticle physicsQuarkoniumHEPconverted photons3. Good healthbottomonium; converted photonsPair productionradiative bottomonium transitionsBaBarBaBar detector at SLACFísica de partículesExperimentsPhysical Review D
researchProduct

Studies of the performance of the ATLAS detector using cosmic-ray muons

2011

Muons from cosmic-ray interactions in the atmosphere provide a high-statistics source of particles that can be used to study the performance and calibration of the ATLAS detector. Cosmic-ray muons can penetrate to the cavern and deposit energy in all detector subsystems. Such events have played an important role in the commissioning of the detector since the start of the installation phase in 2005 and were particularly important for understanding the detector performance in the time prior to the arrival of the first LHC beams. Global cosmic-ray runs were undertaken in both 2008 and 2009 and these data have been used through to the early phases of collision data-taking as a tool for calibrat…

:Mathematics and natural science: 400::Physics: 430 [VDP]ATLAS detector; cosmic-ray muonsPhysics - Instrumentation and DetectorsPhysics and Astronomy (miscellaneous)Physics::Instrumentation and Detectors:Mathematics and natural science: 400::Physics: 430::Nuclear and elementary particle physics: 431 [VDP]Tracking (particle physics)01 natural sciencesHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)Naturvetenskap[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Detectors and Experimental TechniquesPhysicsLarge Hadron ColliderDetectorSettore FIS/01 - Fisica SperimentaleInstrumentation and Detectors (physics.ins-det)ATLASRadiación cósmicamedicine.anatomical_structureComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFísica nuclearLHCNatural SciencesCiências Naturais::Ciências FísicasInstrumentationAstrophysics::High Energy Astrophysical Phenomena:Ciências Físicas [Ciências Naturais]FOS: Physical sciencesddc:500.2530Nuclear physicsAtlas (anatomy)0103 physical sciencesmedicineCalibrationddc:530High Energy Physics[PHYS.PHYS.PHYS-INS-DET]Physics [physics]/Physics [physics]/Instrumentation and Detectors [physics.ins-det]Aerospace engineering010306 general physicsEngineering (miscellaneous)Ciencias ExactasEvent generatorCalorimeterScience & TechnologyCalorimeter (particle physics)ATLAS detectorbusiness.industry010308 nuclear & particles physicsPhysics and Astronomy (miscellaneous); Engineering (miscellaneous)FísicaExperimental High Energy PhysicsHigh Energy Physics::Experimentbusiness
researchProduct

Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real life clinical practice: a nationwide multicenter retrospective observ…

2018

A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in children and adults, based on data from a real-life setting. Demographic, clinical, and therapeutic data from patients treated with ANA and CAN were retrospectively collected and analyzed. Four hundred and seventy five patients were enrolled; ANA and CAN were prescribed in 421 and 105 treatment courses, respectively. During a mean follow-up of 24.39 ± 27.04 months, 89 adverse events (AE) were recorded; 13 (14.61%) were classified as serious AE (sAE). The overall estimated rate of AE and sAE was 8.4 per 100 p…

Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile0301 basic medicineMaleSettore MED/16 - REUMATOLOGIAAutoinflammatory disorders0302 clinical medicineRetrospective StudieAnakinra; Autoinflammatory disorders; Canakinumab; Interleukin-1; Safety profile; RheumatologyChildAntibodies MonoclonalGeneral MedicineMiddle AgedAnakinraTreatment OutcomeAutoinflammationFemaleCohort studymedicine.drugHumanAdultmedicine.medical_specialtyAdolescentLogistic ModelCanakinumabNeutropeniaAntibodies Monoclonal HumanizedAutoimmune DiseaseAutoimmune Diseases03 medical and health sciencesYoung AdultRheumatologyInternal medicineInjection site reactionmedicineHumansAnakinra Autoinflammatory disorders Canakinumab Interleukin-1 Safety profile Adolescent Adult Antibodies Monoclonal Antibodies Monoclonal Humanized Autoimmune Diseases Child Female Humans Interleukin 1 Receptor Antagonist Protein Logistic Models Male Middle Aged Retrospective Studies Treatment Outcome Young AdultAdverse effectRetrospective Studies030203 arthritis & rheumatologyAnakinrabusiness.industryRetrospective cohort studymedicine.diseaseCanakinumabInterleukin 1 Receptor Antagonist ProteinLogistic Models030104 developmental biologyAutoinflammatory disorderSafety profileObservational studybusinessInterleukin-1
researchProduct

Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications

2021

Simple Summary This review proposes a comprehensive overview of the main prognostic systems for HCC classified as prognostic scores, staging systems, or combined systems. Prognostic systems for HCC are usually compared in terms of homogeneity, monotonicity of gradients, and discrimination ability. However, despite the great number of published studies comparing HCC prognostic systems, it is rather difficult to identify a system that could be universally accepted as the best prognostic scheme for all HCC patients encountered in clinical practice. In order to give a contribute in this topic, we conducted a study aimed at externally validate the MESH score and the CNLC classification using the…

Cancer Researchmedicine.medical_specialtyReviewlcsh:RC254-282Prognostic score03 medical and health sciences0302 clinical medicinemedicineIn patientMedical physicsStaging systemmonotonicity of gradientsSettore MED/12 - Gastroenterologiadiscrimination ability; hepatocellular carcinoma; homogeneity; monotonicity of gradients; prognostic performance; prognostic systembusiness.industryprognostic systemExternal validationMono-tonicity of gradienthepatocellular carcinomamedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSettore MED/18homogeneityOncology030220 oncology & carcinogenesisHepatocellular carcinomaPopulation data030211 gastroenterology & hepatologyGeneral healthdiscrimination abilityLiver dysfunctionbusinessprognostic performanceCancers
researchProduct

Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study

2018

Prognostic assessment of patients with hepatocellular carcinoma (HCC) at the time of diagnosis remains controversial and becomes even more complex at the time of restaging when new variables need to be considered. The aim of the current study was to evaluate the prognostic utility of restaging patients before proceeding with additional therapies for HCC. Two independent Italian prospective databases were used to identify 1,196 (training cohort) and 648 (validation cohort) consecutive patients with HCC treated over the same study period (2008-2015) who had complete restaging before decisions about additional therapies. The performance of the Italian Liver Cancer (ITA.LI.CA) prognostic score …

MaleOncologyDatabases FactualLiver cancer; non surgical therapy; prognostic system; surgical therapy; survivalhepatocellular carcinoma stage treatmentKaplan-Meier EstimateCohort StudiesLiver disease0302 clinical medicineMiddle AgedSorafenibPrognosisItaly030220 oncology & carcinogenesisCatheter AblationDisease ProgressionFemale030211 gastroenterology & hepatologysurgical therapyLiver cancerLiver cancermedicine.drugCohort studySorafenibmedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIAClinical Decision-MakingRisk AssessmentsurvivalDisease-Free SurvivalStatistics Nonparametric03 medical and health sciencesnon surgical therapyInternal medicinemedicineHepatectomyHumansInfusions Intra-ArterialNeoplasm InvasivenessSurvival analysisAgedNeoplasm StagingRetrospective StudiesAnalysis of VarianceHepatologybusiness.industryprognostic systemReproducibility of ResultsCancerRetrospective cohort studymedicine.diseaseSurvival AnalysisbusinessProgressive disease
researchProduct

Search for supersymmetric particles in events with lepton pairs and large missing transverse momentum in sqrt{s} = 7 TeV proton-proton collisions wit…

2011

Results are presented of searches for the production of supersymmetric particles decaying into final states with missing transverse momentum and exactly two isolated leptons in √ s = 7 TeV proton–proton collisions at the Large Hadron Collider. Search strategies requiring lepton pairs with identical-sign or opposite-sign electric charges are described. In a data sample corresponding to an integrated luminosity of 35 pb−1 collected with the ATLAS detector, no significant excesses are observed. Based on specific benchmark models, limits are placed on the squark mass between 450 and 690 GeV for squarks approximately degenerate in mass with gluinos, depending on the supersymmetric mass hierarchy…

Physics and Astronomy (miscellaneous)7. Clean energy01 natural sciencesSquarksHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)Local SupersymmetryPions[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Grand Unified TheoryNuclear ExperimentPhysicsLarge Hadron ColliderPhysicsATLAS experimentSettore FIS/01 - Fisica SperimentaleSupersymmetryATLASPhysical SciencesComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFísica nuclearLHCParticle Physics - ExperimentParticle physicsSupergauge TransformationsATLAS experimentFOS: Physical sciencesddc:500.2lepton pairs; proton–proton collisions; ATLAS530Electric chargeNuclear physicsPion0103 physical sciencesFysikddc:530High Energy Physics010306 general physicsEngineering (miscellaneous)FB(-1)Ciencias ExactasStates010308 nuclear & particles physicsHigh Energy Physics::PhenomenologyFísicaGluinosGrand UnificationExperimental High Energy Physicsproton-proton collisionsHigh Energy Physics::ExperimentsupersymmetryMinimal Supersymmetric Standard ModelLeptonModel
researchProduct

RESTOCKING TRIAL OF MELICERTUS KERATHURUS (DECAPODA, PENAEIDAE) IN THE SHALLOW COASTAL WATERS OF SOUTHWESTERN SICILY (MEDITERRANEAN SEA)

2013

Decapoda Aquaculture Coastal management Sicily ChannelSettore BIO/05 - Zoologia
researchProduct

Performance of the ATLAS detector using first collision data

2010

More than half a million minimum-bias events of LHC collision data were collected by the ATLAS experiment in December 2009 at centre-of-mass energies of 0.9 TeV and 2.36 TeV. This paper reports on studies of the initial performance of the ATLAS detector from these data. Comparisons between data and Monte Carlo predictions are shown for distributions of several track- and calorimeter-based quantities. The good performance of the ATLAS detector in these first data gives confidence for successful running at higher energies.

Nuclear and High Energy PhysicsParticle physicsAtlas detectorPhysics::Instrumentation and DetectorsMonte Carlo methodFOS: Physical sciencesddc:500.253001 natural sciences7. Clean energySettore FIS/04 - Fisica Nucleare e SubnucleareHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)LHC ; ATLAS ; Minimum-bias ; 900 GeV ; 2.36 TeV ; PerformanceAtlas (anatomy)0103 physical sciencesmedicine[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]ddc:530High Energy PhysicsDetectors and Experimental Techniques010306 general physicsCiencias ExactasDetectors de radiacióPhysicsHadron-Hadron ScatteringLarge Hadron Collider010308 nuclear & particles physicsATLAS DetectorSettore FIS/01 - Fisica SperimentaleATLAS experimentFísicaATLASCollisionmedicine.anatomical_structureExperimental High Energy PhysicsComputingMethodologies_DOCUMENTANDTEXTPROCESSINGHigh Energy Physics::ExperimentLHCParticle Physics - Experiment
researchProduct